Cytomegalovirus reactivation is frequent in multiple myeloma patients treated with daratumumab‐based regimens

Documenti analoghi

• Mechanisms of resistance to daratumumab in patients with multiple myeloma
  di: Katrine Fladeland Iversen
  Pubblicazione: (2024)
• Efficacy and safety of daratumumab, pomalidomide, and dexamethasone versus daratumumab, carfilzomib, and dexamethasone in daratumumab‐naïve relapsed multiple myeloma
  di: Danai Dima, et al.
  Pubblicazione: (2024)
• The impact of daratumumab pretreatment on multiple myeloma patients undergoing autologous transplantation
  di: Yutaka Shimazu, et al.
  Pubblicazione: (2024)
• Electrophysiological Studies in Combination With Interim‐Positron Emission Tomography Scan for Prevention of Severe Brentuximab‐Vedotin‐Induced Neurotoxicity
  di: Luca Pezzullo, et al.
  Pubblicazione: (2025)
• Safety and feasibility analysis of rapid daratumumab infusion in Chinese patients with multiple myeloma
  di: Xi‐xi Yin, et al.
  Pubblicazione: (2024)